Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial
Crossref DOI link: https://doi.org/10.1007/s00520-015-2907-2
Published Online: 2015-08-27
Published Print: 2016-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lambertini, Matteo
Bruzzi, Paolo
Poggio, Francesca
Pastorino, Simona
Gardin, Giovanni
Clavarezza, Matteo
Bighin, Claudia
Pronzato, Paolo
Del Mastro, Lucia
Text and Data Mining valid from 2015-08-27